Belvedere Trading
GERM

Belvedere Trading’s Amplify Treatments, Testing and Advancements ETF GERM Stock Holding History

Belvedere Trading’s Portfolio GERM Stock Details GERM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-10,313
Closed -$410K – 631
2021
Q2 		$410K Buy
+10,313
New +$385K 0.03% 125

Other funds holding GERM

LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
CAPTRUST Financial Advisors
CAPTRUST Financial Advisors Raleigh, North Carolina $65.5B AUM 24.25% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
APA
American Portfolios Advisors Holbrook, New York $2.36B AUM 14.59% 1-Year Est. Return
IWM
IHT Wealth Management Chicago, Illinois $4.7B AUM 25.67% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
G
Gainplan Bloomfield Hills, Michigan $254M AUM 25.62% 1-Year Est. Return

Belvedere Trading's GERM Position: Q3 2021 in Review

Belvedere Trading sold out of Amplify Treatments, Testing and Advancements ETF (GERM) in Q3 2021, closing a stake of 10,313 shares — an estimated $410K sold.

Belvedere Trading first reported a position in GERM in Q2 2021 and held it in 1 quarter. The position peaked at $410K in Q2 2021. 24 funds tracked by Wall St. Rank hold GERM as of Q3 2021.

  • Belvedere Trading reported no remaining Amplify Treatments, Testing and Advancements ETF position as of Q3 2021 after selling out during the quarter.
  • Belvedere Trading sold 10,313 Amplify Treatments, Testing and Advancements ETF shares in Q3 2021, an estimated $410K.
  • Belvedere Trading first reported a position in Amplify Treatments, Testing and Advancements ETF in Q2 2021 and held it in 1 quarter.
  • Belvedere Trading's Amplify Treatments, Testing and Advancements ETF position peaked at $410K in Q2 2021.
  • 24 funds tracked by Wall St. Rank held Amplify Treatments, Testing and Advancements ETF as of Q3 2021.

Based on Belvedere Trading's 13F filing for Q3 2021, filed 19 Oct 2021.